Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
Neoplasms

About this trial
This is an interventional treatment trial for Neoplasms focused on measuring GSK6097608, Dostarlimab, Dose escalation, Pharmacokinetics, Pharmacodynamics, Advanced solid tumors, First-time-in-human, GSK4428859A, EOS884448, Cobolimab
Eligibility Criteria
Inclusion Criteria:
- Adults 18 years of age or older (or >=20 years of age in Arm-A Japan, Arm-D Japan, Arm E-Japan, and Arm F-Japan);
- Female participants of childbearing potential must agree to use a highly effective form of contraception;
- Histological or cytological documentation of locally advanced, recurrent, or metastatic solid malignancy;
- Disease that has progressed after standard therapy for the specific tumor type, or for which standard therapy has proven to be ineffective, intolerable, or is considered inappropriate, or if no further standard therapy exists;
- Participants in a PK/PD cohort must provide fresh tumor biopsies.
- Eastern cooperative oncology group (ECOG) performance status (PS) 0 to 1
- Life expectancy of at least 12 weeks.
- Adequate organ function as determined by laboratory assessments.
- Adequate cardiac ejection fraction as measured by echocardiogram.
- Arm A-Japan, Arm D-Japan, Arm E-Japan, and Arm F-Japan only: lives in Japan and is racially Japanese, defined as all biological grandparents being Japanese.
- Arm A-China, Arm B-China, Arm D-China, Arm E-China and Arm F-China only: is of Chinese descent and lives in China.
- Arm D, Arm E, and Arm F only: has been deemed suitable for assigned treatment based on assessment by the investigator.
Exclusion Criteria:
- Prior anti-cancer treatment including investigational agents, immune checkpoint inhibitors, chemotherapy, targeted therapy, and biological therapy: within 4 weeks or 5 half-lives of the drug, whichever is shorter.
- Prior allogenic or autologous bone marrow transplantation or other solid organ transplantation.
- Toxicity from previous anticancer treatment, including; greater than or equal to Grade 3 immune-mediated toxicity considered related to prior immunotherapy and that led to treatment discontinuation; or toxicity related to prior treatment that has not resolved; or myocarditis of any grade considered related to prior immuno-oncology therapy that led to treatment discontinuation.
- Known additional malignancy that progressed or required active treatment within the last 2 years.
- Uncontrolled or symptomatic central nervous system (CNS) metastases and/or carcinomatous meningitis.
- Active autoimmune disease that has required systemic disease-modifying or immunosuppressive treatment within the last 2 years.
- Concurrent medical condition requiring the use of systemic immunosuppressive treatment.
- Cirrhosis or current unstable liver or biliary disease per investigator assessment.
- Active infection requiring systemic treatment, known human immunodeficiency virus infection, or positive test for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV)
- Prolonged QT as measured by electrocardiogram.
- Allergen desensitization therapy within 4 weeks of starting study intervention.
- History of hypersensitivity to any of the study interventions or their excipients.
- History or evidence of significant cardiovascular (CV) risk.
- Recent history (within 6 months) of uncontrolled symptomatic ascites or pleural effusions.
- History of idiopathic pulmonary fibrosis; interstitial lung disease; organizing pneumonia; noninfectious pneumonitis that required steroids, or evidence of active, noninfectious pneumonitis.
- Pregnant or lactating woman.
- Receipt of live vaccine within 30 days of the start of study intervention.
- Receipt of transfusion of blood products or administration of colony-stimulating factors within 14 days before the first dose of study intervention.
- Major surgery less than 4 weeks before the first dose of study intervention.
- Known drug or alcohol abuse.
Sites / Locations
- GSK Investigational SiteRecruiting
- GSK Investigational SiteRecruiting
- GSK Investigational SiteRecruiting
- GSK Investigational SiteRecruiting
- GSK Investigational SiteRecruiting
- GSK Investigational SiteRecruiting
- GSK Investigational SiteRecruiting
- GSK investigational SiteRecruiting
- GSK Investigational SiteRecruiting
- GSK Investigational SiteRecruiting
- GSK Investigational SiteRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Participants receiving GSK6097608 monotherapy (Arm A)
Participants receiving GSK6097608 plus dostarlimab (Arm B)
Participants receiving dostarlimab monotherapy (Arm D)
Participants receiving dostarlimab plus GSK4428859A (EOS884448) (Arm E)
Participants receiving dostarlimab plus GSK4428859A (EOS884448) plus GSK6097608 (Arm F)
Participants receiving dostarlimab plus cobolimab (Arm G)
Participants will be administered an intravenous (IV) infusion of GSK6097608 every 3 weeks as monotherapy in escalating doses.
Participants will be administered IV infusion of GSK6097608 every 3 weeks in escalating doses followed by dostarlimab.
Participants will be administered an IV infusion of dostarlimab monotherapy (1 cohort will receive dostarlimab every 3 weeks and 1 cohort will receive dostarlimab every 6 weeks).
Participants will be administered IV infusions of dostarlimab followed by of GSK4428859A (EOS884448), every 3 weeks.
Participants will be administered an IV infusion of dostarlimab followed GSK4428859A (EOS884448) followed by GSK6097608 every 3 weeks.
Participants will be administered an IV infusion of cobolimab followed by dostarlimab